Autopsy report · NCT05269160

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)

“PI is leaving institution and this protocol will not be further pursued at this institution.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 2 months before it started.
• Ran for about 1 year before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Baylor College of Medicine

Sponsor type

University, hospital or other

Conditions

Radiation Dermatitis; Breast Cancer

Interventions

Dermaprazole 1%; Dermaprazole 2%

Participants

3

Sites

2

Countries

United States

Trials that died the same way

• A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease
  “The PI is leaving the institution” (77% match in meaning)
• Hemodynamic Effects Of Impella On Renal Circulation And Risk Of CA-AKI Among Patients Undergoing Protected PCI
  “PI may be leaving the institution” (77% match in meaning)
• Incisional Negative Pressure Wound Therapy
  “PI leaving institution” (75% match in meaning)
• Effects of Nitrous Oxide on Intraocular Pressure
  “PI is no longer at this institution” (74% match in meaning)
• PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
  “Due to PI leaving the institution” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.